myelosuppressive

myelosuppressive

 [mi″ĕ-lo-soo͡-pres´iv]
2. an agent that so acts.

myelosuppressive

/my·elo·sup·pres·sive/ (-sŭ-pres´iv)
2. an agent that so acts.

myelosuppressive

1. inhibiting bone marrow activity, resulting in decreased production of blood cells and platelets.
2. an agent having such properties.
References in periodicals archive ?
Of the 26 patients, 16 died of disease progression, seven died of myelosuppressive infection after chemotherapy, 1 died of second tumor (liver cancer), one died of acute myocardial infarction, and four cases (8.
Myelosuppressive effects are also noted, such as anemia, thrombocytopenia, and leukopenia, and are presumably mediated through c-kit inhibition.
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
Hydroxyurea, a myelosuppressive agent, has been shown to potentially increase the level of HbF and is currently the most effective disease-modifying therapy for both adults and children with SCA.
Decreased immunity due to active infection, myelosuppressive drugs and comorbidities have been reported as risk factors for developing CIN, [18-22] but HIV infection as an independent predictor of CIN in patients with solid tumours has not been reported.
Since then Sanofi Genzyme has conducted studies regarding the potential use of Leukine in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).
The approval is also seeking to treat the effects of concomitant myelosuppressive chemotherapy, in addition to decreasing allogeneic red blood cell transfusions in patients undergoing elective, noncardiac and nonvascular surgery.
In vivo 7 day treatment with recombinant human growth hormone increases the marrow and spleen granulocyte macrophage colony forming units and partially counters the myelosuppressive effects of azidothy-midine7.
7,8) Although this syndrome may present as a multifactorial effect, there are controlled clinical trials describing the myelosuppressive effect of cytotoxic agents that further show its additive effect; for example, Wilson et al.
NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation," The Journal of Clinical Investigation, vol.
Such patients receive more aggressive and myelosuppressive chemotherapies which result in significant dysfunction of mucosal barrier, with alteration in the intestinal microflora which can in turn promote infections with resistant organisms.